Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Knoop

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Immunopharmacology|September 1, 1995
Pharmacodynamics of prophylactic antirejection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantationC J Hesse, T van Gelder, L M Vaessen, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|July 17, 1998
Redundancy of the cytokine network in the development of rejection after clinical heart transplantationC C Baan, C H Holweg, T van Gelder, et al.
Clinical and Experimental Immunology|December 31, 1997
The avidity of allospecific cytotoxic T lymphocytes (CTL) determines their cytokine production profileN E Van Emmerik, C R Daane, C J Knoop, et al.
Clinical Transplantation|October 31, 2001
Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expressionC C Baan, I C van Riemsdijk-van Overbeeke, A H Balk, et al.
Transplantation|March 4, 1998
Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humansT van Gelder, C C Baan, A H Balk, et al.
Transplantation|April 13, 1999
Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantationC C Baan, C J Knoop, T van Gelder, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Immunopharmacology|September 1, 1995
Pharmacodynamics of prophylactic antirejection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantationC J Hesse, T van Gelder, L M Vaessen, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|July 17, 1998
Redundancy of the cytokine network in the development of rejection after clinical heart transplantationC C Baan, C H Holweg, T van Gelder, et al.
Clinical and Experimental Immunology|December 31, 1997
The avidity of allospecific cytotoxic T lymphocytes (CTL) determines their cytokine production profileN E Van Emmerik, C R Daane, C J Knoop, et al.
Clinical Transplantation|October 31, 2001
Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expressionC C Baan, I C van Riemsdijk-van Overbeeke, A H Balk, et al.
Transplantation|March 4, 1998
Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humansT van Gelder, C C Baan, A H Balk, et al.
Transplantation|April 13, 1999
Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantationC C Baan, C J Knoop, T van Gelder, et al.
Pageof 2